#Review🚨
Metabolic dysfunction associated steatotic liver disease #MASLD and alcoholic liver disease #ALD drive liver cancer. Heikenwälder&Co review mechanisms of disease progression and therapeutic advances to reduce cancer risk.
📖👇
Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD) are drivers of liver cancer, promoting its development through chronic liver injury and inflammation. In this Review, Rahbari et al. highlight the distinct pathophysiological mechanisms of progression and therapeutic advancements for MASLD and ALD, emphasizing the need for more tailored approaches to manage these complex diseases and their cancer risks.
